Crinetics Pharmaceuticals, Inc. — Director's Dealing 2022

Apr 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2022-04-04

Reporting Person: Betz Stephen F. (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-04	Common Stock	S	9000	$23.9735	Disposed	116509	Direct

Footnotes

F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $23.9735 per share. The range of sales prices on the transaction date was $23.9515 to $24.0027 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.